Search

Zentalis Pharmaceuticals Inc

Slēgts

2.69 -1.82

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.65

Max

2.74

Galvenie mērījumi

By Trading Economics

Ienākumi

-42M

-78M

EPS

-0.59

Darbinieki

106

EBITDA

-42M

-77M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+220% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-44M

287M

Iepriekšējā atvēršanas cena

4.51

Iepriekšējā slēgšanas cena

2.69

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 25. sept. 23:56 UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, gaining significantly since Friday's close after a recent decline over the past month.

2026. g. 25. sept. 23:55 UTC

AtriCure Inc is trading modestly higher in after-market hours, remaining above its 20-day moving average despite retracing some initial gains.

2026. g. 25. sept. 23:55 UTC

Wendy's Co saw modest gains during after-market hours on Friday, continuing its upward movement but remaining below its 20-day moving average.

2026. g. 25. sept. 23:55 UTC

Lexicon Pharmaceuticals Inc is rising in after-market trading, gaining ground since Friday's close, marking a notable divergence from four consecutive sessions of losses.

2026. g. 25. sept. 23:55 UTC

Cognizant Technology Solutions Corp is trading modestly higher in after-market hours, reaching a peak return since Friday's close, despite remaining below its 20-day moving average.

2026. g. 25. sept. 23:51 UTC

Hamilton Beach Brands Holding Co has advanced in after-market trading, significantly above its 20-day moving average and near the upper end of its one-month range.

2026. g. 25. sept. 23:51 UTC

Social Media

Darden Restaurants Inc reported a rise in sales to $3.2 billion, but net income fell, leading to a decline in stock price in after-market trading.

2026. g. 25. sept. 23:51 UTC

News

CDW Corp completed its acquisition of Lovelytics, enhancing its Services and Solutions portfolio, as shares advanced in after-market trading.

2026. g. 25. sept. 23:51 UTC

Krispy Kreme Inc is advancing in after-market trading, showing a notable increase since Friday's close, despite being below its 20-day moving average.

2026. g. 25. sept. 23:51 UTC

Pacific Biosciences of California Inc is trading lower in after-market hours, reflecting a notable decline since Friday's close and today's sharp loss.

2026. g. 25. sept. 23:51 UTC

News

AbbVie Inc received FDA approval for Juvmo (Tavapadon), a Parkinson's treatment, contributing to a modest rise in shares during after-market trading.

2026. g. 25. sept. 23:51 UTC

Southern Co is trading slightly higher in after-market hours, though its price remains below the 20-day moving average after four consecutive lower closes.

2026. g. 25. sept. 23:51 UTC

Brazil's Industrial Production MoM data release on October 2, 2026, expected to reflect cautious market sentiment amid agricultural sector challenges and external economic pressures.

2026. g. 25. sept. 23:51 UTC

S&P/Case-Shiller Index Forecasts 2.2% Year-over-Year Home Price Increase Amid Mixed Housing Sentiment and Rising Treasury Yields

2026. g. 25. sept. 23:51 UTC

South Korea's S&P Global Manufacturing PMI set for October 1 release amid slowing growth and geopolitical tensions impacting market sentiment.

2026. g. 25. sept. 23:50 UTC

Southern Missouri Bancorp Inc is trading modestly lower in after-market hours, positioned below its 20-day moving average and near the lower end of its one-month range.

2026. g. 25. sept. 23:50 UTC

Upstart Holdings Inc is trading modestly higher in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

2026. g. 25. sept. 23:50 UTC

ABM Industries Inc is down in after-market trading, moving from a slight dip to a more pronounced decline since Friday's close.

2026. g. 25. sept. 23:50 UTC

Arcus Biosciences Inc is trading lower in after-hours, reaching its lowest point of the day and remaining well below its 20-day moving average.

2026. g. 25. sept. 23:50 UTC

Ambarella Inc is rising in after-market trading, continuing its positive trend and remaining significantly above its 20-day moving average.

2026. g. 25. sept. 23:50 UTC

Recursion Pharmaceuticals Inc has advanced in after-market trading, remaining above its 20-day moving average and near the upper end of its one-month trading range.

2026. g. 25. sept. 23:50 UTC

Etsy Inc. has advanced in after-market trading, despite a notable decline from its earlier high and positioning below its 20-day moving average.

2026. g. 25. sept. 23:50 UTC

Baker Hughes Co is trading modestly higher in after-market hours, showing unusual upward movement despite remaining below its 20-day moving average.

2026. g. 25. sept. 23:50 UTC

Altria Group Inc is experiencing a slight increase in after-market trading, advancing since Friday's close despite some unusual activity and price retracement.

2026. g. 25. sept. 23:50 UTC

Medtronic PLC is down in after-market trading, continuing a seven-session trend of lower finishes and remaining significantly below its 20-day moving average.

2026. g. 25. sept. 23:50 UTC

Tencent Music Entertainment Group declined in after-market trading, continuing a downward trend since Friday's close, despite remaining above its 20-day moving average.

2026. g. 25. sept. 23:46 UTC

Parker-Hannifin Corp is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

2026. g. 25. sept. 23:46 UTC

Northern Oil and Gas Inc is trading modestly higher in after-market hours, reaching a peak return since Friday's close, though still below its 20-day moving average.

2026. g. 25. sept. 23:46 UTC

Modest increase in after-market trading, peak return near 0.9%.

2026. g. 25. sept. 23:46 UTC

Correlated Moves

Alaska Air Group Inc's shares are trading roughly flat in after-market hours, reflecting routine activity amid slight gains in the Fidelity Enhanced Small Cap Core ETF.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

220% augšup

Prognoze 12 mēnešiem

Vidējais 8.8 USD  220%

Augstākais 11 USD

Zemākais 5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

5

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.